Increase yields and reduce costs with our innovative upstream process development CDMO solutions.
Once cell lines have been engineered and optimized, cell culture begins as part of upstream process development. Cells are cultured in bioreactors to produce the biologic of interest. Our upstream process development services include fed-batch cultures or continuous perfusion approaches.
What modalities can we handle with our upstream process development?
Processing that continues without interruption. We use single-use bioreactors and intensified perfusion to achieve continuous upstream processing and bring you:
We offer continuous processing as part of our upstream process development or our patented and fully-validated continuous bioprocess manufacturing platform, EnzeneX™.
We are a global CDMO and biosimilar developer dedicated to impacting the global healthcare landscape by bringing trusted and affordable medicines to market, quickly.
Committed to innovation, we have revolutionized biologics production with our patented and validated continuous bioprocess manufacturing platform, EnzeneX™, that enables us to significantly reduce the cost of producing complex biologics and monoclonal antibodies (mAbs).
Our fully-integrated services and productive pipeline of biosimilars, along with our upstream process development solutions, are designed to cater to your project’s every need.
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.